Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

Abraham, 2010, CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen, Breast Cancer Res, 12, R64, 10.1186/bcr2629

Abu-Bakar, 2012, Metabolism of bilirubin by human cytochrome P450 2A6, Toxicol Appl Pharmacol, 261, 15, 10.1016/j.taap.2012.03.010

Achour, 2011, Role of CYP1A1 (T6235C) polymorphism and cigarette smoking in the development of coronary heart disease in Tunisian population, J Genet, 90, 303, 10.1007/s12041-011-0058-x

Agundez, 2004, Cytochrome P450 gene polymorphism and cancer, Curr Drug Metab, 5, 211, 10.2174/1389200043335621

Aitken, 2007, Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes, Drug Metab Dispos, 35, 1687, 10.1124/dmd.107.015511

Aitken, 2006, Regulation of drug-metabolizing enzymes and transporters in inflammation, Annu Rev Pharmacol Toxicol, 46, 123, 10.1146/annurev.pharmtox.46.120604.141059

Aklillu, 2002, Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population, Mol Pharmacol, 61, 586, 10.1124/mol.61.3.586

Al Koudsi, 2010, Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors, Eur J Clin Pharmacol, 66, 239, 10.1007/s00228-009-0762-0

Aleksa, 2005, Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity, Pediatr Nephrol, 20, 872, 10.1007/s00467-004-1807-3

Amador-Noguez, 2007, Alterations in xenobiotic metabolism in the long-lived Little mice, Aging Cell, 6, 453, 10.1111/j.1474-9726.2007.00300.x

Anglicheau, 2007, Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update, Pharmacogenomics, 8, 835, 10.2217/14622416.8.7.835

Anttila, 2003, Methylation of cytochrome P4501A1 promoter in the lung is associated with tobacco smoking, Cancer Res, 63, 8623

2012

Arab-Alameddine, 2009, Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals, Clin Pharmacol Ther, 85, 485, 10.1038/clpt.2008.271

Ariyoshi, 2011, Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262, Drug Metab Dispos, 39, 2045, 10.1124/dmd.111.039586

Aubert, 2011, Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role, Clin Res Hepatol Gastroenterol, 35, 630, 10.1016/j.clinre.2011.04.015

Backes, 2003, Organization of multiple cytochrome P450s with NADPH-cytochrome P450 reductase in membranes, Pharmacol Ther, 98, 221, 10.1016/S0163-7258(03)00031-7

Backman, 2006, Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine, Eur J Clin Pharmacol, 62, 451, 10.1007/s00228-006-0127-x

Backman, 2002, Gemfibrozil greatly increases plasma concentrations of cerivastatin, Clin Pharmacol Ther, 72, 685, 10.1067/mcp.2002.128469

Bahadur, 2002, CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes, Biochem Pharmacol, 64, 1579, 10.1016/S0006-2952(02)01354-0

Baldwin, 2008, Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers, Br J Clin Pharmacol, 65, 767, 10.1111/j.1365-2125.2008.03104.x

Bauer, 2011, Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis, BMJ, 343, d4588, 10.1136/bmj.d4588

Beedanagari, 2010, Role of epigenetic mechanisms in differential regulation of the dioxin-inducible human CYP1A1 and CYP1B1 genes, Mol Pharmacol, 78, 608, 10.1124/mol.110.064899

Beierle, 1999, Gender differences in pharmacokinetics and pharmacodynamics, Int J Clin Pharmacol Ther, 37, 529

Benowitz, 2006, Female sex and oral contraceptive use accelerate nicotine metabolism, Clin Pharmacol Ther, 79, 480, 10.1016/j.clpt.2006.01.008

Benowitz, 2003, Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism, Clin Pharmacol Ther, 74, 468, 10.1016/j.clpt.2003.07.001

Bergmann, 2011, Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer, Pharmacogenomics J, 11, 113, 10.1038/tpj.2010.19

Bergmann, 2011, Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer, Eur J Clin Pharmacol, 67, 693, 10.1007/s00228-011-1007-6

Berlin, 2011, PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2, Pharmacogenet Genomics, 21, 308, 10.1097/FPC.0b013e32833d1011

Bertilsson, 2007, Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects, Clin Pharmacol Ther, 82, 606, 10.1038/sj.clpt.6100358

Bertilsson, 1993, Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine, Lancet, 341, 63, 10.1016/0140-6736(93)92546-6

Bertilsson, 1989, Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype, Clin Pharmacol Ther, 45, 348, 10.1038/clpt.1989.40

Bertino, 2007, Pharmacogenomics of microRNA: a miRSNP towards individualized therapy, Pharmacogenomics, 8, 1625, 10.2217/14622416.8.12.1625

Bièche, 2007, Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues, Pharmacogenet Genomics, 17, 731, 10.1097/FPC.0b013e32810f2e58

Biggs, 2007, Transcription factor binding to a putative double E-box motif represses CYP3A4 expression in human lung cells, Mol Pharmacol, 72, 514, 10.1124/mol.106.033795

Bijl, 2009, Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users, Clin Pharmacol Ther, 85, 45, 10.1038/clpt.2008.172

Birdwell, 2012, The use of a DNA biobank linked to electronic medical records to characterize pharmacogenomic predictors of tacrolimus dose requirement in kidney transplant recipients, Pharmacogenet Genomics, 22, 32, 10.1097/FPC.0b013e32834e1641

Black, 2012, Correlation of CYP2B6, CYP2C19, ABCC4 and SOD2 genotype with outcomes in allogeneic blood and marrow transplant patients, Leuk Res, 36, 59, 10.1016/j.leukres.2011.06.020

Blake, 2007, Ontogeny of dextromethorphan O- and N-demethylation in the first year of life, Clin Pharmacol Ther, 81, 510, 10.1038/sj.clpt.6100101

Bock, 1994, The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes, Pharmacogenetics, 4, 209, 10.1097/00008571-199408000-00005

Bolbrinker, 2012, CYP3A5 genotype–phenotype analysis in the human kidney reveals a strong site-specific expression of CYP3A5 in the proximal tubule in carriers of the CYP3A5*1 allele, Drug Metab Dispos, 40, 639, 10.1124/dmd.111.042648

Bolt, 2003, The cytochrome P-450 isoenzyme CYP2E1 in the biological processing of industrial chemicals: consequences for occupational and environmental medicine, Int Arch Occup Environ Health, 76, 174, 10.1007/s00420-002-0407-4

Boulenc, 2012, Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite, Drug Metab Dispos, 40, 187, 10.1124/dmd.111.040394

Brauch, 2009, Pharmacogenomics of tamoxifen therapy, Clin Chem, 55, 1770, 10.1373/clinchem.2008.121756

Brauch, 2013, Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters, J Clin Oncol, 31, 176, 10.1200/JCO.2012.44.6625

Bray, 2010, Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide, Br J Cancer, 102, 1003, 10.1038/sj.bjc.6605587

Brøsen, 2004, Some aspects of genetic polymorphism in the biotransformation of antidepressants, Therapie, 59, 5, 10.2515/therapie:2004003

Browning, 2010, CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme, Pharmacogenet Genomics, 20, 647, 10.1097/FPC.0b013e32833e90eb

Bu, 2006, A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure–kinetics relationship assessment, Curr Drug Metab, 7, 231, 10.2174/138920006776359329

Buechler, 2011, Does hepatic steatosis affect drug metabolizing enzymes in the liver?, Curr Drug Metab, 12, 24, 10.2174/138920011794520035

Bumpus, 2008, Investigation of the mechanisms underlying the differential effects of the K262R mutation of P450 2B6 on catalytic activity, Mol Pharmacol, 74, 990, 10.1124/mol.108.048637

Bumpus, 2006, Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms, J Pharmacol Exp Ther, 318, 345, 10.1124/jpet.106.102525

Bumpus, 2005, The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation, Drug Metab Dispos, 33, 795, 10.1124/dmd.105.003749

Bunten, 2011, CYP2B6 and OPRM1 gene variations predict methadone-related deaths, Addict Biol, 16, 142, 10.1111/j.1369-1600.2010.00274.x

Burger, 2006, Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism, Br J Clin Pharmacol, 61, 148, 10.1111/j.1365-2125.2005.02536.x

Burk, 2005, Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor, Mol Pharmacol, 67, 1954, 10.1124/mol.104.009019

Burk, 2004, The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR), J Biol Chem, 279, 38379, 10.1074/jbc.M404949200

Burk, 2002, Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine, J Biol Chem, 277, 24280, 10.1074/jbc.M202345200

Buters, 1999, Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas, Proc Natl Acad Sci U S A, 96, 1977, 10.1073/pnas.96.5.1977

Cairns, 1996, Characterization of the human cytochrome P4502D6 promoter. A potential role for antagonistic interactions between members of the nuclear receptor family, J Biol Chem, 271, 25269, 10.1074/jbc.271.41.25269

Caraco, 1997, Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects, J Pharmacol Exp Ther, 281, 330

Carbonell, 2010, CYP2C9*3 loss-of-function allele is associated with acute upper gastrointestinal bleeding related to the use of NSAIDs other than aspirin, Clin Pharmacol Ther, 87, 693, 10.1038/clpt.2010.33

Caro, 2004, Oxidative stress, toxicology, and pharmacology of CYP2E1, Annu Rev Pharmacol Toxicol, 44, 27, 10.1146/annurev.pharmtox.44.101802.121704

Cederbaum, 2006, CYP2E1–biochemical and toxicological aspects and role in alcohol-induced liver injury, Mt Sinai J Med, 73, 657

Chang, 2003, Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver, Toxicol Sci, 71, 11, 10.1093/toxsci/71.1.11

Chang, 1993, Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes, Cancer Res, 53, 5629

Chavarria-Soley, 2008, Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme, Hum Mutat, 29, 1147, 10.1002/humu.20786

Chehal, 2006, Cytochrome p450 2C (CYP2C) in ischemic heart injury and vascular dysfunction, Can J Physiol Pharmacol, 84, 15, 10.1139/y05-139

Chen, 2009, The transcriptional regulation of the human CYP2C genes, Curr Drug Metab, 10, 567, 10.2174/138920009789375397

Chen, 2009, Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo, J Pharmacol Exp Ther, 329, 908, 10.1124/jpet.109.152017

Choudhary, 2008, Characterization of the biochemical and structural phenotypes of four CYP1B1 mutations observed in individuals with primary congenital glaucoma, Pharmacogenet Genomics, 18, 665, 10.1097/FPC.0b013e3282ff5a36

Christensen, 1998, The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis, Pharmacogenetics, 8, 473, 10.1097/00008571-199812000-00003

Coller, 2002, The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver, Br J Clin Pharmacol, 54, 157, 10.1046/j.1365-2125.2002.01614.x

Collet, 2009, Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study, Lancet, 373, 309, 10.1016/S0140-6736(08)61845-0

Corchero, 2001, The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4alpha on the disposition of debrisoquine in the mouse, Mol Pharmacol, 60, 1260, 10.1124/mol.60.6.1260

Cornelis, 2004, Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction, J Med Genet, 41, 758, 10.1136/jmg.2004.022012

Cornelis, 2006, Coffee, CYP1A2 genotype, and risk of myocardial infarction, JAMA, 295, 1135, 10.1001/jama.295.10.1135

Cornelis, 2011, Genome-wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption, PLoS Genet, 7, e1002033, 10.1371/journal.pgen.1002033

Cotreau, 2005, The influence of age and sex on the clearance of cytochrome P450 3A substrates, Clin Pharmacokinet, 44, 33, 10.2165/00003088-200544010-00002

Crane, 2012, Effect of CYP2B6*6 and CYP2C19*2 genotype on chlorpyrifos metabolism, Toxicology, 293, 115, 10.1016/j.tox.2012.01.006

Crespi, 1997, The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase, Pharmacogenetics, 7, 203, 10.1097/00008571-199706000-00005

Cresteil, 1998, Onset of xenobiotic metabolism in children: toxicological implications, Food Addit Contam, 15 Suppl., 45, 10.1080/02652039809374614

Crettol, 2005, Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment, Clin Pharmacol Ther, 78, 593, 10.1016/j.clpt.2005.08.011

Crisafulli, 2011, Pharmacogenetics of antidepressants, Front Pharmacol, 2, 6, 10.3389/fphar.2011.00006

Croom, 2009, Human hepatic CYP2B6 developmental expression: the impact of age and genotype, Biochem Pharmacol, 78, 184, 10.1016/j.bcp.2009.03.029

Cui, 2012, Association of the CYP1B1 Leu432Val polymorphism with the risk of prostate cancer: a meta-analysis, Mol Biol Rep, 39, 7465, 10.1007/s11033-012-1579-y

Dai, 2001, Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid, Pharmacogenetics, 11, 597, 10.1097/00008571-200110000-00006

Daily, 2009, Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies, Pharmacogenomics, 10, 1489, 10.2217/pgs.09.82

Daly, 2006, Significance of the minor cytochrome P450 3A isoforms, Clin Pharmacokinet, 45, 13, 10.2165/00003088-200645010-00002

Dannenberg, 2006, Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation, BMC Genomics, 7, 181, 10.1186/1471-2164-7-181

Dansette, 2011, Cytochromes P450 catalyze both steps of the major pathway of clopidogrel bioactivation, whereas paraoxonase catalyzes the formation of a minor thiol metabolite isomer, Chem Res Toxicol, 25, 348, 10.1021/tx2004085

Darbar, 2006, Pharmacogenetics of antiarrhythmic therapy, Expert Opin Pharmacother, 7, 1583, 10.1517/14656566.7.12.1583

Das, 2008, Enzyme induction and cytotoxicity in human hepatocytes by chlorpyrifos and N, N-diethyl-m-toluamide (DEET), Drug Metabol Drug Interact, 23, 237, 10.1515/DMDI.2008.23.3-4.237

De Jonge, 2011, In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients, Clin Pharmacol Ther, 90, 414, 10.1038/clpt.2011.130

De Leon, 2009, DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping, CNS Spectr, 14, 19, 10.1017/S1092852900020022

De Morais, 1994, Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese, Mol Pharmacol, 46, 594

De Morais, 1994, The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans, J Biol Chem, 269, 15419, 10.1016/S0021-9258(17)40694-6

Dehal, 1997, CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver, Cancer Res, 57, 3402

Delozier, 2007, Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues, Drug Metab Dispos, 35, 682, 10.1124/dmd.106.012823

Desta, 2011, Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age, Clin Pharmacol Ther, 90, 693, 10.1038/clpt.2011.174

Desta, 2007, Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro, Pharmacogenomics, 8, 547, 10.2217/14622416.8.6.547

Desta, 2002, Clinical significance of the cytochrome P450 2C19 genetic polymorphism, Clin Pharmacokinet, 41, 913, 10.2165/00003088-200241120-00002

Dhir, 2003, Interpulse growth hormone secretion in the episodic plasma profile causes the sex reversal of cytochrome P450s in senescent male rats, Proc Natl Acad Sci U S A, 100, 15224, 10.1073/pnas.2434273100

Di Iulio, 2009, In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function, Pharmacogenet Genomics, 19, 300, 10.1097/FPC.0b013e328328d577

Di, 2009, Structure, function, regulation and polymorphism of human cytochrome P450 2A6, Curr Drug Metab, 10, 754, 10.2174/138920009789895507

Diczfalusy, 2011, 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans, Br J Clin Pharmacol, 71, 183, 10.1111/j.1365-2125.2010.03773.x

Ding, 2003, Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts, Annu Rev Pharmacol Toxicol, 43, 149, 10.1146/annurev.pharmtox.43.100901.140251

Ding, 1995, Expression and alternative splicing of the cytochrome P-450 CYP2A7, Biochem J, 306, 161, 10.1042/bj3060161

Djordjevic, 2010, Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2–163C>A polymorphism, Eur J Clin Pharmacol, 66, 697, 10.1007/s00228-010-0823-4

Dobrinas, 2011, Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility, Clin Pharmacol Ther, 90, 117, 10.1038/clpt.2011.70

Dobrinas, 2012, Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking, Pharmacogenet Genomics, 22, 143, 10.1097/FPC.0b013e32834e9e1a

Druesne-Pecollo, 2009, Alcohol and genetic polymorphisms: effect on risk of alcohol-related cancer, Lancet Oncol, 10, 173, 10.1016/S1470-2045(09)70019-1

Du, 2006, Effects of the differentiated keratinocyte phenotype on expression levels of CYP1-4 family genes in human skin cells, Toxicol Appl Pharmacol, 213, 135, 10.1016/j.taap.2005.10.003

Duniec-Dmuchowski, 2007, Regulation of CYP3A4 and CYP2B6 expression by liver X receptor agonists, Biochem Pharmacol, 74, 1535, 10.1016/j.bcp.2007.07.040

Dutheil, 2008, Xenobiotic metabolizing enzymes in the central nervous system: contribution of cytochrome P450 enzymes in normal and pathological human brain, Biochimie, 90, 426, 10.1016/j.biochi.2007.10.007

Dutheil, 2009, Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function, Drug Metab Dispos, 37, 1528, 10.1124/dmd.109.027011

Dvorak, 2003, Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation, Mol Pharmacol, 64, 160, 10.1124/mol.64.1.160

Eap, 2007, Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers, Clin Pharmacol Ther, 81, 719, 10.1038/sj.clpt.6100120

Eckhardt, 1998, Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation, Pain, 76, 27, 10.1016/S0304-3959(98)00021-9

Economopoulos, 2010, Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: A meta-analysis, Breast Cancer Res Treat, 122, 545, 10.1007/s10549-009-0728-z

Edginton, 2008, Physiology-based simulations of a pathological condition: prediction of pharmacokinetics in patients with liver cirrhosis, Clin Pharmacokinet, 47, 743, 10.2165/00003088-200847110-00005

Eichelbaum, 1979, Defective N-oxidation of sparteine in man: a new pharmacogenetic defect, Eur J Clin Pharmacol, 16, 183, 10.1007/BF00562059

Eissing, 2011, A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks, Front Physiol, 2, 4, 10.3389/fphys.2011.00004

Elbekai, 2004, The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes, Curr Drug Metab, 5, 157, 10.2174/1389200043489054

Elens, 2011, Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study, Pharmacogenet Genomics, 21, 861, 10.1097/FPC.0b013e32834c6edb

Elens, 2011, A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients, Clin Chem, 57, 1574, 10.1373/clinchem.2011.165613

Elens, 2011, Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors' dose requirements and trough blood levels in stable renal transplant patients, Pharmacogenomics, 12, 1383, 10.2217/pgs.11.90

Endrizzi, 2002, Discriminative quantification of cytochrome P4502D6 and 2D7/8 pseudogene expression by TaqMan real-time reverse transcriptase polymerase chain reaction, Anal Biochem, 300, 121, 10.1006/abio.2001.5453

Engel, 1996, Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation, Clin Pharmacol Ther, 59, 613, 10.1016/S0009-9236(96)90001-6

Estany-Gestal, 2011, Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: a systematic critical review, Pharmacogenet Genomics, 21, 357, 10.1097/FPC.0b013e328346d2bb

Faucette, 2000, Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity, Drug Metab Dispos, 28, 1222

Faucette, 2006, Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor, J Pharmacol Exp Ther, 317, 1200, 10.1124/jpet.105.098160

Faucette, 2004, Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers, Drug Metab Dispos, 32, 348, 10.1124/dmd.32.3.348

Faucette, 2007, Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers, J Pharmacol Exp Ther, 320, 72, 10.1124/jpet.106.112136

Feidt, 2010, Profiling induction of cytochrome p450 enzyme activity by statins using a new liquid chromatography-tandem mass spectrometry cocktail assay in human hepatocytes, Drug Metab Dispos, 38, 1589, 10.1124/dmd.110.033886

Ferguson, 2011, Cytochrome P450 enzymes in the brain: emerging evidence of biological significance, Trends Pharmacol Sci, 32, 708, 10.1016/j.tips.2011.08.005

Finn, 2007, Conditional deletion of cytochrome P450 oxidoreductase in the liver and gastrointestinal tract: a new model for studying the functions of the P450 system, J Pharmacol Exp Ther, 322, 40, 10.1124/jpet.107.121780

Flück, 2011, Clinical and biochemical consequences of p450 oxidoreductase deficiency, Endocr Dev, 20, 63, 10.1159/000321221

Flück, 2008, P450 oxidoreductase deficiency — a new form of congenital adrenal hyperplasia, Endocr Dev, 13, 67, 10.1159/000134826

Flück, 2004, Mutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley–Bixler syndrome, Nat Genet, 36, 228, 10.1038/ng1300

Foti, 2010, Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation, Drug Metab Dispos, 38, 981, 10.1124/dmd.110.032094

Frank, 2007, Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping, Eur J Clin Pharmacol, 63, 321, 10.1007/s00228-006-0250-8

Friedman, 2009, Most mammalian mRNAs are conserved targets of microRNAs, Genome Res, 19, 92, 10.1101/gr.082701.108

Frueh, 2004, From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community, Pharmacogenomics, 5, 571, 10.1517/14622416.5.5.571

Fuhr, 2007, Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the “cocktail” approach, Clin Pharmacol Ther, 81, 270, 10.1038/sj.clpt.6100050

Fujita, 2008, CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1, Cancer Sci, 99, 1049, 10.1111/j.1349-7006.2008.00773.x

Fukami, 2007, A novel duplication type of CYP2A6 gene in African-American population, Drug Metab Dispos, 35, 515, 10.1124/dmd.106.013557

Furuta, 1998, Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer, Ann Intern Med, 129, 1027, 10.7326/0003-4819-129-12-199812150-00006

Furuta, 2007, Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori, Clin Pharmacol Ther, 81, 521, 10.1038/sj.clpt.6100043

Furuta, 2004, Pharmacogenomics of proton pump inhibitors, Pharmacogenomics, 5, 181, 10.1517/phgs.5.2.181.27483

Fux, 2005, Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study, Clin Pharmacol Ther, 78, 378, 10.1016/j.clpt.2005.07.004

Gaedigk, 2000, Interethnic differences of drug-metabolizing enzymes, Int J Clin Pharmacol Ther, 38, 61, 10.5414/CPP38061

Gaedigk, 2006, Variability of CYP2J2 expression in human fetal tissues, J Pharmacol Exp Ther, 319, 523, 10.1124/jpet.106.109215

Gaedigk, 2005, CYP2D7 splice variants in human liver and brain: does CYP2D7 encode functional protein?, Biochem Biophys Res Commun, 336, 1241, 10.1016/j.bbrc.2005.08.255

Gaedigk, 2010, Identification of novel CYP2D7-2D6 hybrids: non-functional and functional variants, Front Pharmacol, 1, 121, 10.3389/fphar.2010.00121

Gaedigk, 2012, CYP2D6, SULT1A1 and UGT2B17 copy number variation: quantitative detection by multiplex PCR, Pharmacogenomics, 13, 91, 10.2217/pgs.11.135

Gamazon, 2011, A study of CNVs as trait-associated polymorphisms and as expression quantitative trait loci, PLoS Genet, 7, e1001292, 10.1371/journal.pgen.1001292

Gamazon, 2009, A pharmacogene database enhanced by the 1000 Genomes Project, Pharmacogenet Genomics, 19, 829, 10.1097/FPC.0b013e3283317bac

Gandhi, 2004, Sex differences in pharmacokinetics and pharmacodynamics, Annu Rev Pharmacol Toxicol, 44, 499, 10.1146/annurev.pharmtox.44.101802.121453

Gao, 2010, Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug–drug interactions, Xenobiotica, 40, 467, 10.3109/00498254.2010.487163

Garcia-Martin, 2004, Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms, Clin Pharmacol Ther, 76, 119, 10.1016/j.clpt.2004.04.006

Gasche, 2004, Codeine intoxication associated with ultrarapid CYP2D6 metabolism, N Engl J Med, 351, 2827, 10.1056/NEJMoa041888

Gatanaga, 2007, Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26, Clin Infect Dis, 45, 1230, 10.1086/522175

Gatanaga, 2009, Successful genotype-tailored treatment with small-dose efavirenz, AIDS, 23, 433, 10.1097/QAD.0b013e32831940e3

Gay, 2010, Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution, Mol Pharmacol, 77, 529, 10.1124/mol.109.062570

Geisler, 2008, CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation, Pharmacogenomics, 9, 1251, 10.2217/14622416.9.9.1251

Gelston, 2012, Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects, Br J Clin Pharmacol, 73, 786, 10.1111/j.1365-2125.2011.04145.x

Gervot, 1999, Human CYP2B6: expression, inducibility and catalytic activities, Pharmacogenetics, 9, 295, 10.1097/00008571-199906000-00004

Ghobadi, 2008, CYP2D6 is primarily responsible for the metabolism of clomiphene, Drug Metab Pharmacokinet, 23, 101, 10.2133/dmpk.23.101

Ghotbi, 2007, Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype–phenotype relationship in Swedes and Koreans, Eur J Clin Pharmacol, 63, 537, 10.1007/s00228-007-0288-2

Ghotbi, 2009, Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers, Pharmacogenomics J, 9, 208, 10.1038/tpj.2009.4

Glaeser, 2005, Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes, Br J Clin Pharmacol, 59, 199, 10.1111/j.1365-2125.2004.02265.x

Glubb, 2012, Liver expression quantitative trait loci: a foundation for pharmacogenomic research, Front Genet, 3, 153, 10.3389/fgene.2012.00153

Gnerre, 2004, Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene, Pharmacogenetics, 14, 635, 10.1097/00008571-200410000-00001

Goetz, 2007, The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen, Breast Cancer Res Treat, 101, 113, 10.1007/s10549-006-9428-0

Goldstein, 2001, Clinical relevance of genetic polymorphisms in the human CYP2C subfamily, Br J Clin Pharmacol, 52, 349, 10.1046/j.0306-5251.2001.01499.x

Gomes, 2009, Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation, Pharmacogenomics, 10, 579, 10.2217/pgs.09.7

Gómez-Lechón, 2009, Cytochrome p450 and steatosis, Curr Drug Metab, 10, 692, 10.2174/138920009789895543

Gonzalez, 2007, The 2006 Bernard B. Brodie Award Lecture. Cyp2e1, Drug Metab Dispos, 35, 1, 10.1124/dmd.106.012492

Granfors, 2004, Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro, Br J Clin Pharmacol, 57, 349, 10.1046/j.1365-2125.2003.02028.x

Griese, 1998, Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population, Pharmacogenetics, 8, 15, 10.1097/00008571-199802000-00003

Gu, 2003, Liver-specific deletion of the NADPH-cytochrome P450 reductase gene: impact on plasma cholesterol homeostasis and the function and regulation of microsomal cytochrome P450 and heme oxygenase, J Biol Chem, 278, 25895, 10.1074/jbc.M303125200

Guengerich, 2008, Cytochrome P450 and chemical toxicology, Chem Res Toxicol, 21, 70, 10.1021/tx700079z

Guengerich, 2011, Orphans in the human cytochrome P450 superfamily: approaches to discovering functions and relevance in pharmacology, Pharmacol Rev, 63, 684, 10.1124/pr.110.003525

Gunes, 2008, Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms, Pharmacogenomics, 9, 625, 10.2217/14622416.9.5.625

Haas, 2004, Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study, AIDS, 18, 2391

Haberl, 2005, Three haplotypes associated with CYP2A6 phenotypes in Caucasians, Pharmacogenet Genomics, 15, 609, 10.1097/01.fpc.0000171517.22258.f1

Han, 2002, Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2, Br J Clin Pharmacol, 54, 540, 10.1046/j.1365-2125.2002.01686.x

Hara, 2002, Contribution of hepatocyte nuclear factor-4 to down-regulation of CYP2D6 gene expression by nitric oxide, Mol Pharmacol, 61, 194, 10.1124/mol.61.1.194

Hart, 2008, Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism, Pharmacogenet Genomics, 18, 11, 10.1097/FPC.0b013e3282f2f121

He, 2011, Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development, Curr Med Chem, 18, 667, 10.2174/092986711794480131

Heim, 1992, Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6, Genomics, 14, 49, 10.1016/S0888-7543(05)80282-4

Helsby, 2012, Molecular mechanisms of genetic variation and transcriptional regulation of CYP2C19, Front Genet, 3, 206, 10.3389/fgene.2012.00206

Helsby, 2011, Which CYP2B6 variants have functional consequences for cyclophosphamide bioactivation?, Drug Metab Dispos, 40, 635, 10.1124/dmd.111.043646

Hendrychová, 2011, Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations, Biochim Biophys Acta, 1814, 58, 10.1016/j.bbapap.2010.07.017

Henningsson, 2005, Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel, Clin Cancer Res, 11, 8097, 10.1158/1078-0432.CCR-05-1152

Hesse, 2004, Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes, Pharmacogenetics, 14, 225, 10.1097/00008571-200404000-00002

Hesselink, 2003, Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus, Clin Pharmacol Ther, 74, 245, 10.1016/S0009-9236(03)00168-1

Hiemke, 2000, Pharmacokinetics of selective serotonin reuptake inhibitors, Pharmacol Ther, 85, 11, 10.1016/S0163-7258(99)00048-0

Higashi, 2007, Human CYP2A6 is induced by estrogen via estrogen receptor, Drug Metab Dispos, 35, 1935, 10.1124/dmd.107.016568

Hodgson, 2007, The importance of cytochrome P450 2B6 in the human metabolism of environmental chemicals, Pharmacol Ther, 113, 420, 10.1016/j.pharmthera.2006.10.002

Hoffman, 2001, Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19, Pharmacogenetics, 11, 687, 10.1097/00008571-200111000-00007

Hofmann, 2008, Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver, J Pharmacol Exp Ther, 325, 284, 10.1124/jpet.107.133306

Holmes, 2011, CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis, JAMA, 306, 2704, 10.1001/jama.2011.1880

Holstein, 2005, Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents, Br J Clin Pharmacol, 60, 103, 10.1111/j.1365-2125.2005.02379.x

Holzhütter, 2012, The virtual liver: a multidisciplinary, multilevel challenge for systems biology, Wiley Interdiscip Rev Syst Biol Med, 4, 221, 10.1002/wsbm.1158

Holzinger, 2012, Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants, Pharmacogenet Genomics, 22, 858, 10.1097/FPC.0b013e32835a450b

Honda, 2011, Functional characterization of CYP2B6 allelic variants in demethylation of antimalarial artemether, Drug Metab Dispos, 39, 1860, 10.1124/dmd.111.040352

Huang, 2008, Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations, Proc Natl Acad Sci U S A, 105, 1733, 10.1073/pnas.0711621105

Huang, 2005, Diversity and function of mutations in p450 oxidoreductase in patients with Antley–Bixler syndrome and disordered steroidogenesis, Am J Hum Genet, 76, 729, 10.1086/429417

Huang, 2008, New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process, J Clin Pharmacol, 48, 662, 10.1177/0091270007312153

Hulot, 2006, Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, 108, 2244, 10.1182/blood-2006-04-013052

Hustert, 2001, The genetic determinants of the CYP3A5 polymorphism, Pharmacogenetics, 11, 773, 10.1097/00008571-200112000-00005

Ingelman-Sundberg, 2005, Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity, Pharmacogenomics J, 5, 6, 10.1038/sj.tpj.6500285

Ingelman-Sundberg, 2010, The past, present and future of pharmacoepigenomics, Pharmacogenomics, 11, 625, 10.2217/pgs.10.59

Innocenti, 2011, Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue, PLoS Genet, 7, e1002078, 10.1371/journal.pgen.1002078

Irvin, 2011, Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study, J Clin Oncol, 29, 3232, 10.1200/JCO.2010.31.4427

Itoh, 2006, Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha, J Pharmacol Exp Ther, 319, 693, 10.1124/jpet.106.107573

Jain, 2005, Applications of AmpliChip CYP450, Mol Diagn, 9, 119

Jang, 2012, Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel, Am J Cardiol, 110, 502, 10.1016/j.amjcard.2012.04.020

Jansson, 2001, Effect of two mutations of human CYP1B1, G61E and R469W, on stability and endogenous steroid substrate metabolism, Pharmacogenetics, 11, 793, 10.1097/00008571-200112000-00007

Jaquenoud Sirot, 2009, ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine, J Clin Psychopharmacol, 29, 319, 10.1097/JCP.0b013e3181acc372

Jennewein, 2010, MicroRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferator-activated receptor gamma (PPARgamma) mRNA destabilization, J Biol Chem, 285, 11846, 10.1074/jbc.M109.066399

Jiang, 2005, Toward the evaluation of function in genetic variability: characterizing human SNP frequencies and establishing BAC-transgenic mice carrying the human CYP1A1_CYP1A2 locus, Hum Mutat, 25, 196, 10.1002/humu.20134

Jiang, 2006, Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype, Pharmacogenet Genomics, 16, 359, 10.1097/01.fpc.0000204994.99429.46

Jin, 2007, Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects, Clin Pharmacol Ther, 82, 579, 10.1038/sj.clpt.6100208

Johansson, 2008, CNVs of human genes and their implication in pharmacogenetics. Cytogenet, Genome Res, 123, 195

Johansson, 1993, Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine, Proc Natl Acad Sci U S A, 90, 11825, 10.1073/pnas.90.24.11825

Johnson, 2004, Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen, Breast Cancer Res Treat, 85, 151, 10.1023/B:BREA.0000025406.31193.e8

Johnstone, 2006, Determinants of the rate of nicotine metabolism and effects on smoking behavior, Clin Pharmacol Ther, 80, 319, 10.1016/j.clpt.2006.06.011

Jonas, 2009, Genetic and clinical factors relating to warfarin dosing, Trends Pharmacol Sci, 30, 375, 10.1016/j.tips.2009.05.001

Jorge-Nebert, 2010, Analysis of human CYP1A1 and CYP1A2 genes and their shared bidirectional promoter in eight world populations, Hum Mutat, 31, 27, 10.1002/humu.21132

Josephson, 2007, CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir, Clin Pharmacol Ther, 81, 708, 10.1038/sj.clpt.6100117

Joshi, 2006, Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine, Neuropharmacology, 50, 568, 10.1016/j.neuropharm.2005.11.001

Jover, 2002, Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved, FASEB J, 16, 1799, 10.1096/fj.02-0195fje

Jover, 2009, Transcriptional regulation of cytochrome p450 genes by the nuclear receptor hepatocyte nuclear factor 4-alpha, Curr Drug Metab, 10, 508, 10.2174/138920009788898000

Kamdem, 2006, Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B1, Chem Res Toxicol, 19, 577, 10.1021/tx050358e

Kang, 2008, Bioactivation of flutamide metabolites by human liver microsomes, Drug Metab Dispos, 36, 1425, 10.1124/dmd.108.020370

Karbiener, 2009, microRNA miR-27b impairs human adipocyte differentiation and targets PPARgamma, Biochem Biophys Res Commun, 390, 247, 10.1016/j.bbrc.2009.09.098

Kaur-Knudsen, 2009, Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52,000 individuals, Pharmacogenomics J, 9, 327, 10.1038/tpj.2009.34

Kaur-Knudsen, 2009, CYP1B1 genotype and risk of cardiovascular disease, pulmonary disease, and cancer in 50,000 individuals, Pharmacogenet Genomics, 19, 685, 10.1097/FPC.0b013e32833042cb

Kawakami, 2011, Simultaneous absolute quantification of 11 cytochrome P450 isoforms in human liver microsomes by liquid chromatography tandem mass spectrometry with in silico target peptide selection, J Pharm Sci, 100, 341, 10.1002/jps.22255

Kawashima, 2006, Involvement of hepatocyte nuclear factor 4alpha in the different expression level between CYP2C9 and CYP2C19 in the human liver, Drug Metab Dispos, 34, 1012, 10.1124/dmd.106.009365

Kazui, 2010, Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite, Drug Metab Dispos, 38, 92, 10.1124/dmd.109.029132

Kerb, 2009, Pharmacogenetics of antimalarial drugs: effect on metabolism and transport, Lancet Infect Dis, 9, 760, 10.1016/S1473-3099(09)70320-2

Keshava, 2004, CYP3A4 polymorphisms–potential risk factors for breast and prostate cancer: a HuGE review, Am J Epidemiol, 160, 825, 10.1093/aje/kwh294

Kim, 2007, The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression, Pharmacol Ther, 113, 88, 10.1016/j.pharmthera.2006.07.004

Kim, 1995, Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms, Clin Pharmacol Ther, 57, 645, 10.1016/0009-9236(95)90227-9

Kimura, 1989, The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene, Am J Hum Genet, 45, 889

King, 2008, Clinical impact of patient population differences and genomic variation in efavirenz therapy, AIDS, 22, 1709, 10.1097/QAD.0b013e32830163ad

King, 2002, Cloning of CYP2J2 gene and identification of functional polymorphisms, Mol Pharmacol, 61, 840, 10.1124/mol.61.4.840

Kinirons, 2004, Drug metabolism and ageing, Br J Clin Pharmacol, 57, 540, 10.1111/j.1365-2125.2004.02096.x

Kirchheiner, 2003, Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6, Pharmacogenetics, 13, 619, 10.1097/00008571-200310000-00005

Kirchheiner, 2004, Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response, Mol Psychiatry, 9, 442, 10.1038/sj.mp.4001494

Kirchheiner, 2006, Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype, Clin Pharmacol Ther, 80, 657, 10.1016/j.clpt.2006.09.008

Kisselev, 2005, Association of CYP1A1 polymorphisms with differential metabolic activation of 17beta-estradiol and estrone, Cancer Res, 65, 2972, 10.1158/0008-5472.CAN-04-3543

Kitada, 2003, Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6, Int J Clin Pharmacol Res, 23, 31

Kiyotani, 2010, Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients, J Clin Oncol, 28, 1287, 10.1200/JCO.2009.25.7246

Kiyotani, 2012, Dose-adjustment study of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients, Breast Cancer Res Treat, 131, 137, 10.1007/s10549-011-1777-7

Klein, 2009, Estimation of the warfarin dose with clinical and pharmacogenetic data, N Engl J Med, 360, 753, 10.1056/NEJMoa0809329

Klein, 2005, Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz, Pharmacogenet Genomics, 15, 861, 10.1097/01213011-200512000-00004

Klein, 2012, PPARA: a novel genetic determinant of CYP3A4 in vitro and in vivo, Clin Pharmacol Ther, 91, 1044, 10.1038/clpt.2011.336

Klein, 2010, Pathway-targeted pharmacogenomics of CYP1A2 in human liver, Front Pharmacol, 1

Klotz, 2006, Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem, Int J Clin Pharmacol Ther, 44, 297, 10.5414/CPP44297

Klotz, 2007, Antiarrhythmics: elimination and dosage considerations in hepatic impairment, Clin Pharmacokinet, 46, 985, 10.2165/00003088-200746120-00002

Klotz, 2004, CYP2C19 polymorphism and proton pump inhibitors, Basic Clin Pharmacol Toxicol, 95, 2, 10.1111/j.1600-0773.2004.pto950102.x

Knockaert, 2011, Mechanisms of mitochondrial targeting of cytochrome P450 2E1: physiopathological role in liver injury and obesity, FEBS J, 278, 4252, 10.1111/j.1742-4658.2011.08357.x

Koch, 2002, Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA, Drug Metab Dispos, 30, 1108, 10.1124/dmd.30.10.1108

Komatsu, 2000, Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes, Drug Metab Dispos, 28, 1457

Koren, 2006, Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother, Lancet, 368, 704, 10.1016/S0140-6736(06)69255-6

Kosaki, 2004, A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam, Brain Dev, 26, 530, 10.1016/j.braindev.2004.02.010

Koukouritaki, 2004, Developmental expression of human hepatic CYP2C9 and CYP2C19, J Pharmacol Exp Ther, 308, 965, 10.1124/jpet.103.060137

Kramer, 2008, Novel CYP2C9 promoter variants and assessment of their impact on gene expression, Mol Pharmacol, 73, 1751, 10.1124/mol.107.044149

Kranendonk, 2008, Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley–Bixler syndrome variants of cytochrome P450 oxidoreductase, Arch Biochem Biophys, 475, 93, 10.1016/j.abb.2008.04.014

Kreth, 2000, Identification of the human cytochromes P450 involved in the oxidative metabolism of “Ecstasy”-related designer drugs, Biochem Pharmacol, 59, 1563, 10.1016/S0006-2952(00)00284-7

Kubota, 2006, CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation, Pharmacogenomics J, 6, 115, 10.1038/sj.tpj.6500348

Kuehl, 2001, Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression, Nat Genet, 27, 383, 10.1038/86882

Küpfer, 1984, Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man, Eur J Clin Pharmacol, 26, 753, 10.1007/BF00541938

Kurzawski, 2006, Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients, Eur J Clin Pharmacol, 62, 877, 10.1007/s00228-006-0183-2

Lafite, 2007, Selective, competitive and mechanism-based inhibitors of human cytochrome P450 2J2, Arch Biochem Biophys, 464, 155, 10.1016/j.abb.2007.03.028

Laganà, 2009, miRò: a miRNA knowledge base, Database (Oxford), 2009, bap008, 10.1093/database/bap008

Lai, 2009, Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms, Curr Drug Metab, 10, 1009, 10.2174/138920009790711832

Laika, 2010, Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome, Pharmacogenomics J, 10, 20, 10.1038/tpj.2009.32

Lake, 2011, Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease, Drug Metab Dispos, 39, 1954, 10.1124/dmd.111.040592

Lamba, 2005, Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics, Curr Drug Metab, 6, 369, 10.2174/1389200054633880

Lamba, 2008, Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression, Drug Metab Dispos, 36, 169, 10.1124/dmd.107.016600

Lamba, 2003, Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression, J Pharmacol Exp Ther, 307, 906, 10.1124/jpet.103.054866

Lamba, 2010, Genetic predictors of interindividual variability in hepatic CYP3A4 expression, J Pharmacol Exp Ther, 332, 1088, 10.1124/jpet.109.160804

Lang, 2001, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver, Pharmacogenetics, 11, 399, 10.1097/00008571-200107000-00004

Lang, 2004, Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles, J Pharmacol Exp Ther, 311, 34, 10.1124/jpet.104.068973

Langenfeld, 2009, Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liver, Proteomics, 9, 2313, 10.1002/pmic.200800680

Läpple, 2003, Differential expression and function of CYP2C isoforms in human intestine and liver, Pharmacogenetics, 13, 565, 10.1097/00008571-200309000-00005

Leclerc, 2010, Profiling gene expression of whole cytochrome P450 superfamily in human bronchial and peripheral lung tissues: differential expression in non-small cell lung cancers, Biochimie, 92, 292, 10.1016/j.biochi.2009.12.007

Lee, 2013, Clinical application of CYP2C19 pharmacogenetics toward more personalized medicine, Front Genet, 3

Lee, 2008, Genetic polymorphism of hepatocyte nuclear factor-4alpha influences human cytochrome P450 2D6 activity, Hepatology, 48, 635, 10.1002/hep.22396

Lee, 2002, Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data, Pharmacogenetics, 12, 251, 10.1097/00008571-200204000-00010

Lee, 2008, Global patterns of variation in allele and haplotype frequencies and linkage disequilibrium across the CYP2E1 gene, Pharmacogenomics J, 8, 349, 10.1038/tpj.2008.9

Lee, 2010, Identification of novel substrates for human cytochrome P450 2J2, Drug Metab Dispos, 38, 347, 10.1124/dmd.109.030270

Leeder, 2005, Variability of CYP3A7 expression in human fetal liver, J Pharmacol Exp Ther, 314, 626, 10.1124/jpet.105.086504

Lehr, 2011, Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine, Pharmacogenet Genomics, 21, 721, 10.1097/FPC.0b013e32834a522e

Leppert, 2011, CYP2D6 in the metabolism of opioids for mild to moderate pain, Pharmacology, 87, 274, 10.1159/000326085

Leskelä, 2011, Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity, Pharmacogenomics J, 11, 121, 10.1038/tpj.2010.13

Levran, 2011, CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction, Addict Biol

Lewis, 2004, Substrates of human cytochromes P450 from families CYP1 and CYP2: analysis of enzyme selectivity and metabolism, Drug Metabol Drug Interact, 20, 111, 10.1515/DMDI.2004.20.3.111

Li, 2002, Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate, J Pharmacol Exp Ther, 300, 399, 10.1124/jpet.300.2.399

Li, 2010, Synergistically enhanced CYP2B6 inducibility between a polymorphic mutation in CYP2B6 promoter and pregnane X receptor activation, Mol Pharmacol, 78, 704, 10.1124/mol.110.065185

Li, 2012, Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment, Pharmacogenomics, 13, 555, 10.2217/pgs.11.160

Li, 2000, Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol, Pharmacogenetics, 10, 343, 10.1097/00008571-200006000-00008

Li, 2012, Association of CYP1A1 polymorphisms with prostate cancer risk: an updated meta-analysis, Mol Biol Rep, 39, 10273, 10.1007/s11033-012-1904-5

Lieber, 1997, Cytochrome P-4502E1: its physiological and pathological role, Physiol Rev, 77, 517, 10.1152/physrev.1997.77.2.517

Lin, 2007, Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy, Curr Drug Metab, 8, 109, 10.2174/138920007779816002

Lin, 2002, Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism, Mol Pharmacol, 62, 162, 10.1124/mol.62.1.162

Liu, 2007, Drugs as CYP3A probes, inducers, and inhibitors, Drug Metab Rev, 39, 699, 10.1080/03602530701690374

Liu, 2008, The far and distal enhancers in the CYP3A4 gene co-ordinate the proximal promoter in responding similarly to the pregnane X receptor but differentially to hepatocyte nuclear factor-4alpha, Biochem J, 409, 243, 10.1042/BJ20070613

Li-Wan-Po, 2010, Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17, Br J Clin Pharmacol, 69, 222, 10.1111/j.1365-2125.2009.03578.x

Lobo, 2008, In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine, Clin Pharmacokinet, 47, 191, 10.2165/00003088-200847030-00005

Löfgren, 2009, Regulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormone, Drug Metab Dispos, 37, 1505, 10.1124/dmd.109.026963

Lu, 2008, CYP2E1 and oxidative liver injury by alcohol, Free Radic Biol Med, 44, 723, 10.1016/j.freeradbiomed.2007.11.004

Lu, 2008, Characteristics of the amiodarone-warfarin interaction during long-term follow-up, Am J Health Syst Pharm, 65, 947, 10.2146/ajhp060415

Lubomirov, 2011, Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study, J Infect Dis, 203, 246, 10.1093/infdis/jiq043

Lubomirov, 2010, ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir, Pharmacogenet Genomics, 20, 217, 10.1097/FPC.0b013e328336eee4

Lunshof, 2012, Pharmacogenomic testing: knowing more, doing better, Clin Pharmacol Ther, 91, 387, 10.1038/clpt.2011.339

Lutz, 2002, Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism, Pharmacogenetics, 12, 73, 10.1097/00008571-200201000-00010

MacArthur, 2012, A systematic survey of loss-of-function variants in human protein-coding genes, Science, 335, 823, 10.1126/science.1215040

Madadi, 2012, Pharmacogenetics of opioids for the treatment of acute maternal pain during pregnancy and lactation, Curr Drug Metab, 13, 721, 10.2174/138920012800840392

Madadi, 2009, Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case–control study, Clin Pharmacol Ther, 85, 31, 10.1038/clpt.2008.157

Madlensky, 2011, Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes, Clin Pharmacol Ther, 89, 718, 10.1038/clpt.2011.32

Maglich, 2002, Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification, Mol Pharmacol, 62, 638, 10.1124/mol.62.3.638

Mahgoub, 1977, Polymorphic hydroxylation of Debrisoquine in man, Lancet, 2, 584, 10.1016/S0140-6736(77)91430-1

Mahungu, 2009, Cytochrome P450 2B6 516G–>T is associated with plasma concentrations of nevirapine at both 200mg twice daily and 400 mg once daily in an ethnically diverse population, HIV Med, 10, 310, 10.1111/j.1468-1293.2008.00689.x

Maimbo, 2011, CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans, Eur J Clin Pharmacol, 68, 267, 10.1007/s00228-011-1118-0

Malaiyandi, 2006, Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy, Mol Psychiatry, 11, 400, 10.1038/sj.mp.4001794

Manolopoulos, 2011, Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective, Pharmacogenomics, 12, 1161, 10.2217/pgs.11.65

Marohnic, 2010, Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect, Drug Metab Dispos, 38, 332, 10.1124/dmd.109.030445

Marth, 2011, The functional spectrum of low-frequency coding variation, Genome Biol, 12, R84, 10.1186/gb-2011-12-9-r84

Martinez-Jiménez, 2005, Transcriptional regulation of the human hepatic CYP3A4: identification of a new distal enhancer region responsive to CCAAT/enhancer-binding protein beta isoforms (liver activating protein and liver inhibitory protein), Mol Pharmacol, 67, 2088, 10.1124/mol.104.008169

Matsubara, 2008, Role of vitamin D receptor in the lithocholic acid-mediated CYP3A induction in vitro and in vivo, Drug Metab Dispos, 36, 2058, 10.1124/dmd.108.021501

Matsumoto, 2002, Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole, Drug Metab Dispos, 30, 1240, 10.1124/dmd.30.11.1240

Matsumura, 2004, Identification of a novel polymorphic enhancer of the human CYP3A4 gene, Mol Pharmacol, 65, 326, 10.1124/mol.65.2.326

McCarver, 1998, A genetic polymorphism in the regulatory sequences of human CYP2E1: association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake, Toxicol Appl Pharmacol, 152, 276, 10.1006/taap.1998.8532

Mega, 2009, Cytochrome p-450 polymorphisms and response to clopidogrel, N Engl J Med, 360, 354, 10.1056/NEJMoa0809171

Mehlotra, 2007, CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment, Br J Clin Pharmacol, 64, 391, 10.1111/j.1365-2125.2007.02884.x

Melanson, 2010, Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation, Am J Hematol, 85, 967, 10.1002/ajh.21889

Meyer, 2004, Pharmacogenetics — five decades of therapeutic lessons from genetic diversity, Nat Rev Genet, 5, 669, 10.1038/nrg1428

Meyer, 1997, Molecular mechanisms of genetic polymorphisms of drug metabolism, Annu Rev Pharmacol Toxicol, 37, 269, 10.1146/annurev.pharmtox.37.1.269

Michaud, 2010, Metabolic activity and mRNA levels of human cardiac CYP450s involved in drug metabolism, PLoS One, 5, e15666, 10.1371/journal.pone.0015666

Miksys, 2003, Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain, Neuropharmacology, 45, 122, 10.1016/S0028-3908(03)00136-9

Miksys, 2002, Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics, J Neurochem, 82, 1376, 10.1046/j.1471-4159.2002.01069.x

Mikus, 2011, Pharmacogenomics of the triazole antifungal agent voriconazole, Pharmacogenomics, 12, 861, 10.2217/pgs.11.18

Miller, 2011, Consequences of POR mutations and polymorphisms, Mol Cell Endocrinol, 336, 174, 10.1016/j.mce.2010.10.022

Millonig, 2011, Ethanol-mediated carcinogenesis in the human esophagus implicates CYP2E1 induction and the generation of carcinogenic DNA-lesions, Int J Cancer, 128, 533, 10.1002/ijc.25604

Mishra, 2007, A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance, Proc Natl Acad Sci U S A, 104, 13513, 10.1073/pnas.0706217104

Mohri, 2010, Human CYP2E1 is regulated by miR-378, Biochem Pharmacol, 79, 1045, 10.1016/j.bcp.2009.11.015

Mori, 2007, Hepatic transcript levels for genes coding for enzymes associated with xenobiotic metabolism are altered with age, Toxicol Pathol, 35, 242, 10.1080/01926230601156286

Mörike, 2008, Propafenone for the prevention of atrial tachyarrhythmias after cardiac surgery: a randomized, double-blind placebo-controlled trial, Clin Pharmacol Ther, 84, 104, 10.1038/sj.clpt.6100473

Murai, 2009, Deactivation of anti-cancer drug letrozole to a carbinol metabolite by polymorphic cytochrome P450 2A6 in human liver microsomes, Xenobiotica, 39, 795, 10.3109/00498250903171395

Mürdter, 2011, Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites, Hum Mol Genet, 21, 1145, 10.1093/hmg/ddr543

Mürdter, 2011, Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma, Clin Pharmacol Ther, 89, 708, 10.1038/clpt.2011.27

Murray, 2001, Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1, Annu Rev Pharmacol Toxicol, 41, 297, 10.1146/annurev.pharmtox.41.1.297

Murray, 1997, Tumor-specific expression of cytochrome P450 CYP1B1, Cancer Res, 57, 3026

Muschler, 2009, The role of human CYP2C8 and CYP2C9 variants in pioglitazone metabolism in vitro, Basic Clin Pharmacol Toxicol, 105, 374, 10.1111/j.1742-7843.2009.00457.x

Mwenifumbo, 2007, Genetic variability in CYP2A6 and the pharmacokinetics of nicotine, Pharmacogenomics, 8, 1385, 10.2217/14622416.8.10.1385

Mwenifumbo, 2009, Molecular genetics of nicotine metabolism, Handb Exp Pharmacol, 235, 10.1007/978-3-540-69248-5_9

Mwenifumbo, 2010, New CYP2A6 gene deletion and conversion variants in a population of Black African descent, Pharmacogenomics, 11, 189, 10.2217/pgs.09.144

Mwinyi, 2010, Regulation of CYP2C19 expression by estrogen receptor α: implications for estrogen-dependent inhibition of drug metabolism, Mol Pharmacol, 78, 886, 10.1124/mol.110.065540

Mwinyi, 2011, The ligands of estrogen receptor α regulate cytochrome P4502C9 (CYP2C9) expression, J Pharmacol Exp Ther, 338, 302, 10.1124/jpet.110.175075

Mwinyi, 2010, New insights into the regulation of CYP2C9 gene expression: the role of the transcription factor GATA-4, Drug Metab Dispos, 38, 415, 10.1124/dmd.109.029405

Naik, 2013, Molecular interactions between NAFLD and xenobiotic metabolism, Front Genet, 4

Nakajima, 2006, Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations, Clin Pharmacol Ther, 80, 282, 10.1016/j.clpt.2006.05.012

Nakajima, 2007, Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients, Pharmacogenet Genomics, 17, 431, 10.1097/FPC.0b013e328045c4fb

Nakajima, 1999, Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans, J Biochem, 125, 803, 10.1093/oxfordjournals.jbchem.a022352

Nakamura, 2012, Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1–98 trial, J Natl Cancer Inst, 104, 1264, 10.1093/jnci/djs304

Napoli, 2009, The Val432Leu polymorphism of the CYP1B1 gene is associated with differences in estrogen metabolism and bone density, Bone, 44, 442, 10.1016/j.bone.2008.09.018

Naraharisetti, 2010, Human liver expression of CYP2C8: gender, age, and genotype effects, Drug Metab Dispos, 38, 889, 10.1124/dmd.109.031542

Neafsey, 2009, Genetic polymorphism in CYP2E1: population distribution of CYP2E1 activity, J Toxicol Environ Health B Crit Rev, 12, 362, 10.1080/10937400903158359

Nebert, 2006, The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis, Nat Rev Cancer, 6, 947, 10.1038/nrc2015

Nebert, 2004, Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer, J Biol Chem, 279, 23847, 10.1074/jbc.R400004200

Nebert, 2008, Endogenous functions of the aryl hydrocarbon receptor (AHR): intersection of cytochrome P450 1 (CYP1)-metabolized eicosanoids and AHR biology, J Biol Chem, 283, 36061, 10.1074/jbc.R800053200

Nebert, 2002, Clinical importance of the cytochromes P450, Lancet, 360, 1155, 10.1016/S0140-6736(02)11203-7

Nelson, 2004, Cytochrome P450 nomenclature, 2004, Methods Mol Biol, 320, 1

Nelson, 2004, Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants, Pharmacogenetics, 14, 1, 10.1097/00008571-200401000-00001

Nielsen, 1994, Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms, Clin Pharmacol Ther, 55, 518, 10.1038/clpt.1994.65

Niemi, 2003, Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide, Clin Pharmacol Ther, 74, 380, 10.1016/S0009-9236(03)00228-5

Niwa, 2008, Heterotropic cooperativity in oxidation mediated by cytochrome p450, Curr Drug Metab, 9, 453, 10.2174/138920008784746364

Node, 1999, Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids, Science, 285, 1276, 10.1126/science.285.5431.1276

Nyakutira, 2008, High prevalence of the CYP2B6 516G–>T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe, Eur J Clin Pharmacol, 64, 357, 10.1007/s00228-007-0412-3

Ogilvie, 2006, Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug–drug interactions, Drug Metab Dispos, 34, 191, 10.1124/dmd.105.007633

Ohlsson Rosenborg, 2008, Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects, Eur J Clin Pharmacol, 64, 1175, 10.1007/s00228-008-0529-z

Ohtsuki, 2012, Simultaneous absolute protein quantification of transporters, cytochrome P450s and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities, Drug Metab Dispos, 40, 83, 10.1124/dmd.111.042259

Oneda, 2009, The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test, Pharmacogenet Genomics, 19, 877, 10.1097/FPC.0b013e32833225e7

Oneta, 2002, Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase, J Hepatol, 36, 47, 10.1016/S0168-8278(01)00223-9

Onica, 2008, Dexamethasone-mediated up-regulation of human CYP2A6 involves the glucocorticoid receptor and increased binding of hepatic nuclear factor 4 alpha to the proximal promoter, Mol Pharmacol, 73, 451, 10.1124/mol.107.039354

Onizuka, 2011, Cytochrome P450 genetic polymorphisms influence the serum concentration of calcineurin inhibitors in allogeneic hematopoietic SCT recipients, Bone Marrow Transplant, 46, 1113, 10.1038/bmt.2010.273

Otto, 2003, Identification of novel roles of the cytochrome p450 system in early embryogenesis: effects on vasculogenesis and retinoic acid homeostasis, Mol Cell Biol, 23, 6103, 10.1128/MCB.23.17.6103-6116.2003

Ou, 2011, MicroRNA hsa-miR-613 targets the human LXRα gene and mediates a feedback loop of LXRα autoregulation, Mol Endocrinol, 25, 584, 10.1210/me.2010-0360

Ou-Yang, 2000, Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population, Br J Clin Pharmacol, 49, 145, 10.1046/j.1365-2125.2000.00128.x

Ozdemir, 2000, Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method, Pharmacogenetics, 10, 373, 10.1097/00008571-200007000-00001

Paine, 2006, The human intestinal cytochrome P450 “pie”, Drug Metab Dispos, 34, 880, 10.1124/dmd.105.008672

Palatini, 2009, CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension, J Hypertens, 27, 1594, 10.1097/HJH.0b013e32832ba850

Palma, 2010, Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression, Pharmacogenomics J, 10, 478, 10.1038/tpj.2010.2

Pan, 2009, MicroRNAs regulate CYP3A4 expression via direct and indirect targeting, Drug Metab Dispos, 37, 2112, 10.1124/dmd.109.027680

Pang, 2009, Predicting potentially functional SNPs in drug-response genes, Pharmacogenomics, 10, 639, 10.2217/pgs.09.12

Parikh, 2007, Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa, Clin Pharmacol Ther, 82, 197, 10.1038/sj.clpt.6100122

Pascussi, 2008, The tangle of nuclear receptors that controls xenobiotic metabolism and transport: crosstalk and consequences, Annu Rev Pharmacol Toxicol, 48, 1, 10.1146/annurev.pharmtox.47.120505.105349

Patsopoulos, 2005, CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis, Pharmacogenet Genomics, 15, 151, 10.1097/01213011-200503000-00003

Pavek, 2008, Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues, Curr Drug Metab, 9, 129, 10.2174/138920008783571774

Pedersen, 2006, The effects of human CYP2C8 genotype and fluvoxamine on the pharmacokinetics of rosiglitazone in healthy subjects, Br J Clin Pharmacol, 62, 682, 10.1111/j.1365-2125.2006.02706.x

Pelkonen, 2000, CYP2A6: a human coumarin 7-hydroxylase, Toxicology, 144, 139, 10.1016/S0300-483X(99)00200-0

Penno, 1981, Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins, Proc Natl Acad Sci U S A, 78, 5193, 10.1073/pnas.78.8.5193

Penzak, 2007, Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda, HIV Med, 8, 86, 10.1111/j.1468-1293.2007.00432.x

Perera, 2010, The missing linkage: what pharmacogenetic associations are left to find in CYP3A?, Expert Opin Drug Metab Toxicol, 6, 17, 10.1517/17425250903379546

Perera, 2009, Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans, Pharmacogenomics J, 9, 49, 10.1038/tpj.2008.13

Pharoah, 2012, Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1–98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients, J Natl Cancer Inst, 104, 1263, 10.1093/jnci/djs312

Pilotto, 2007, Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms, Gastroenterology, 133, 465, 10.1053/j.gastro.2007.05.025

Pirmohamed, 2009, The applications of pharmacogenetics to prescribing: what is currently practicable?, Clin Med, 9, 493, 10.7861/clinmedicine.9-5-493

Qiu, 2010, The unique complexity of the CYP3A4 upstream region suggests a nongenetic explanation of its expression variability, Pharmacogenet Genomics, 20, 167, 10.1097/FPC.0b013e328336bbeb

Raccor, 2012, Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo, Drug Metab Dispos, 40, 54, 10.1124/dmd.111.039347

Rae, 2012, CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients, J Natl Cancer Inst, 104, 452, 10.1093/jnci/djs126

Rahmioglu, 2012, Genome-wide association study reveals a complex genetic architecture underpinning-induced CYP3A4 enzyme activity, Eur J Drug Metab Pharmacokinet

Raimundo, 2004, A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects, Clin Pharmacol Ther, 76, 128, 10.1016/j.clpt.2004.04.009

Rakhmanina, 2010, Efavirenz in the therapy of HIV infection, Expert Opin Drug Metab Toxicol, 6, 95, 10.1517/17425250903483207

Rakhshandehroo, 2009, Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human, PLoS One, 4, e6796, 10.1371/journal.pone.0006796

Rasmussen, 2002, The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors, Pharmacogenetics, 12, 473, 10.1097/00008571-200208000-00008

Rau, 2009, Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study, Clin Pharmacol Ther, 85, 269, 10.1038/clpt.2008.218

Raunio, 2005, Regulation of CYP3A genes in the human respiratory tract, Chem Biol Interact, 151, 53, 10.1016/j.cbi.2003.12.007

Raunio, 2012, CYP2A6: genetics, structure, regulation, and function, Drug Metabol Drug Interact, 27, 73, 10.1515/dmdi-2012-0001

Raunio, 2001, Polymorphisms of CYP2A6 and its practical consequences, Br J Clin Pharmacol, 52, 357, 10.1046/j.0306-5251.2001.01500.x

Rebbeck, 1998, Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4, J Natl Cancer Inst, 90, 1225, 10.1093/jnci/90.16.1225

Rebsamen, 2009, The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction, Pharmacogenomics J, 9, 34, 10.1038/tpj.2008.7

Regan, 2012, CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1–98 trial, J Natl Cancer Inst, 104, 441, 10.1093/jnci/djs125

Relling, 1992, Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities, Clin Pharmacol Ther, 52, 643, 10.1038/clpt.1992.203

Rettie, 2005, Clinical and toxicological relevance of CYP2C9: drug–drug interactions and pharmacogenetics, Annu Rev Pharmacol Toxicol, 45, 477, 10.1146/annurev.pharmtox.45.120403.095821

Ribaudo, 2006, Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study, Clin Infect Dis, 42, 401, 10.1086/499364

Ribaudo, 2010, Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study, J Infect Dis, 202, 717, 10.1086/655470

Rieder, 2005, Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose, N Engl J Med, 352, 2285, 10.1056/NEJMoa044503

Rieger, 2011, MIRNA-DISTILLER: a stand-alone application to compile microRNA data from databases, Front Genet, 2, 39, 10.3389/fgene.2011.00039

Roberts, 2011, The structural basis for homotropic and heterotropic cooperativity of midazolam metabolism by human cytochrome P450 3A4, Biochemistry, 50, 10804, 10.1021/bi200924t

Rocha, 2009, Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia, Leukemia, 23, 545, 10.1038/leu.2008.323

Rodriguez-Antona, 2003, Transcriptional regulation of human CYP3A4 basal expression by CCAAT enhancer-binding protein alpha and hepatocyte nuclear factor-3 gamma, Mol Pharmacol, 63, 1180, 10.1124/mol.63.5.1180

Rodriguez-Antona, 2010, Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment, Hum Genet, 127, 1, 10.1007/s00439-009-0748-0

Rodríguez-Antona, 2008, Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism, Pharmacogenomics J, 8, 268, 10.1038/sj.tpj.6500482

Rodríguez-Antona, 2005, Phenotype–genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles, Biochem Biophys Res Commun, 338, 299, 10.1016/j.bbrc.2005.09.020

Rosemary, 2007, The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance, Curr Clin Pharmacol, 2, 93, 10.2174/157488407779422302

Rossini, 2008, CYP2A6 polymorphisms and risk for tobacco-related cancers, Pharmacogenomics, 9, 1737, 10.2217/14622416.9.11.1737

Rostami-Hodjegan, 2007, Simulation and prediction of in vivo drug metabolism in human populations from in vitro data, Nat Rev Drug Discov, 6, 140, 10.1038/nrd2173

Rotger, 2007, Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals, Clin Pharmacol Ther, 81, 557, 10.1038/sj.clpt.6100072

Rowland, 2006, Crystal structure of human cytochrome P450 2D6, J Biol Chem, 281, 7614, 10.1074/jbc.M511232200

Roy, 2005, CYP3A5 genetic polymorphisms in different ethnic populations, Drug Metab Dispos, 33, 884, 10.1124/dmd.105.003822

Sachse, 1997, Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences, Am J Hum Genet, 60, 284

Sachse, 1999, Functional significance of a C–>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine, Br J Clin Pharmacol, 47, 445, 10.1046/j.1365-2125.1999.00898.x

Sadee, 2012, The relevance of “missing heritability” in pharmacogenomics, Clin Pharmacol Ther, 92, 428, 10.1038/clpt.2012.116

Sadee, 2011, Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy, Clin Pharmacol Ther, 89, 355, 10.1038/clpt.2010.314

Sakuyama, 2008, Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47–51, 53–55, and 57), Drug Metab Dispos, 36, 2460, 10.1124/dmd.108.023242

Sandee, 2010, Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro, Pharmacogenet Genomics, 20, 677, 10.1097/FPC.0b013e32833f4f9b

Sansen, 2007, Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2, J Biol Chem, 282, 14348, 10.1074/jbc.M611692200

Saussele, 2007, Selective induction of human hepatic cytochromes P450 2B6 and 3A4 by metamizole, Clin Pharmacol Ther, 82, 265, 10.1038/sj.clpt.6100138

Schadt, 2008, Mapping the genetic architecture of gene expression in human liver, PLoS Biol, 6, e107, 10.1371/journal.pbio.0060107

Schaeffeler, 2003, CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR, Hum Mutat, 22, 476, 10.1002/humu.10280

Schirmer, 2007, Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes, Pharmacogenomics, 8, 443, 10.2217/14622416.8.5.443

Schmeier, 2011, dPORE-miRNA: polymorphic regulation of microRNA genes, PLoS One, 6, e16657, 10.1371/journal.pone.0016657

Schmidt, 2001, Gender difference in ifosfamide metabolism by human liver microsomes, Eur J Drug Metab Pharmacokinet, 26, 193, 10.1007/BF03190396

Schröder, 2011, Inferring statin-induced gene regulatory relationships in primary human hepatocytes, Bioinformatics, 27, 2473, 10.1093/bioinformatics/btr416

Schröder, 2013, Genomics of ADME gene expression: mapping expression quantitative trait loci relevant for absorption, distribution, metabolism and excretion of drugs in human liver, Pharmacogenomics J, 13, 12, 10.1038/tpj.2011.44

Schroth, 2007, Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes, J Clin Oncol, 25, 5187, 10.1200/JCO.2007.12.2705

Schroth, 2009, Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen, JAMA, 302, 1429, 10.1001/jama.2009.1420

Schults, 2010, Diminished carcinogen detoxification is a novel mechanism for hypoxia-inducible factor 1-mediated genetic instability, J Biol Chem, 285, 14558, 10.1074/jbc.M109.076323

Schwab, 2005, Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data, Clin Pharmacol Ther, 78, 627, 10.1016/j.clpt.2005.08.017

Schwab, 2011, Warfarin pharmacogenetics meets clinical use, Blood, 118, 2938, 10.1182/blood-2011-07-367763

Schwab, 2004, CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori, Clin Pharmacol Ther, 76, 201, 10.1016/j.clpt.2004.05.002

Schwartz, 2007, The current state of knowledge on age, sex, and their interactions on clinical pharmacology, Clin Pharmacol Ther, 82, 87, 10.1038/sj.clpt.6100226

Scordo, 2006, No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population, Pharmacol Res, 53, 162, 10.1016/j.phrs.2005.10.005

Scott, 2005, Structures of cytochrome P450 3A4, Trends Biochem Sci, 30, 5, 10.1016/j.tibs.2004.11.004

Scott, 2009, CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing, Pharmacogenomics, 10, 1243, 10.2217/pgs.09.71

Sergentanis, 2009, Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis, Breast Cancer Res Treat, 122, 459, 10.1007/s10549-009-0694-5

Shah, 2011, Structures of cytochrome P450 2B6 bound to 4-benzylpyridine and 4-(4-nitrobenzyl)pyridine: insight into inhibitor binding and rearrangement of active site side chains, Mol Pharmacol, 80, 1047, 10.1124/mol.111.074427

Shaik, 2009, CYP1A1 polymorphisms and risk of prostate cancer: a meta-analysis, Urol J, 6, 78

Shen, 2002, Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase, J Biol Chem, 277, 6536, 10.1074/jbc.M111408200

Shi, 2008, CYP1A1 and GSTM1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis, Lung Cancer, 59, 155, 10.1016/j.lungcan.2007.08.004

Shimada, 1996, Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations, Xenobiotica, 26, 395, 10.3109/00498259609046718

Shimada, 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians, J Pharmacol Exp Ther, 270, 414

Shimamoto, 2000, Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele, Eur J Clin Pharmacol, 56, 65, 10.1007/s002280050722

Sibbing, 2010, Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement, Circulation, 121, 512, 10.1161/CIRCULATIONAHA.109.885194

Siegle, 2001, Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain, Pharmacogenetics, 11, 237, 10.1097/00008571-200104000-00007

Sim, 2005, CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele, Pharmacogenet Genomics, 15, 625, 10.1097/01.fpc.0000171516.84139.89

Sim, 2009, Nomenclature for alleles of the cytochrome P450 oxidoreductase gene, Pharmacogenet Genomics, 19, 565, 10.1097/FPC.0b013e32832af5b7

Sim, 2006, A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants, Clin Pharmacol Ther, 79, 103, 10.1016/j.clpt.2005.10.002

Simon, 2009, Genetic determinants of response to clopidogrel and cardiovascular events, N Engl J Med, 360, 363, 10.1056/NEJMoa0808227

Slaviero, 2003, Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy, Lancet Oncol, 4, 224, 10.1016/S1470-2045(03)01034-9

Sofi, 2011, Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis, Pharmacogenomics J, 11, 199, 10.1038/tpj.2010.21

Spiecker, 2004, Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2, Circulation, 110, 2132, 10.1161/01.CIR.0000143832.91812.60

Spurdle, 2002, The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer, Pharmacogenetics, 12, 355, 10.1097/00008571-200207000-00003

Staatz, 2010, Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I, Clin Pharmacokinet, 49, 141, 10.2165/11317350-000000000-00000

Staatz, 2010, Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II, Clin Pharmacokinet, 49, 207, 10.2165/11317550-000000000-00000

Stamer, 2010, Personalized therapy in pain management: where do we stand?, Pharmacogenomics, 11, 843, 10.2217/pgs.10.47

Stanton, 2012, Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1–98 trial, J Natl Cancer Inst, 104, 1265, 10.1093/jnci/djs305

Steimer, 2005, Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy, Clin Chem, 51, 376, 10.1373/clinchem.2004.041327

Stevens, 2006, New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology, Drug Discov Today, 11, 440, 10.1016/j.drudis.2006.03.002

Stevens, 2008, Developmental changes in human liver CYP2D6 expression, Drug Metab Dispos, 36, 1587, 10.1124/dmd.108.021873

Stiborová, 2005, Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers, Cancer Lett, 220, 145, 10.1016/j.canlet.2004.07.036

Stingl, 2012, Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function, Mol Psychiatry

Su, 2000, Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, Cancer Res, 60, 5074

Sueyoshi, 1999, The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene, J Biol Chem, 274, 6043, 10.1074/jbc.274.10.6043

Sulem, 2011, Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption, Hum Mol Genet, 20, 2071, 10.1093/hmg/ddr086

Surendiran, 2011, Influence of CYP2C9 gene polymorphisms on response to glibenclamide in type 2 diabetes mellitus patients, Eur J Clin Pharmacol, 67, 797, 10.1007/s00228-011-1013-8

Tai, 2002, Association between the PPARA L162V polymorphism and plasma lipid levels: the Framingham Offspring Study, Arterioscler Thromb Vasc Biol, 22, 805, 10.1161/01.ATV.0000012302.11991.42

Takagi, 2010, MicroRNAs regulate human hepatocyte nuclear factor 4alpha, modulating the expression of metabolic enzymes and cell cycle, J Biol Chem, 285, 4415, 10.1074/jbc.M109.085431

Takagi, 2008, Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4, J Biol Chem, 283, 9674, 10.1074/jbc.M709382200

Takahashi, 1993, Induction of cytochrome P-4502E1 in the human liver by ethanol is caused by a corresponding increase in encoding messenger RNA, Hepatology, 17, 236

Takanashi, 2000, CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates, Pharmacogenetics, 10, 95, 10.1097/00008571-200003000-00001

Talakad, 2009, Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs, Drug Metab Dispos, 37, 644, 10.1124/dmd.108.023655

Tan, 2001, Expression of cytochrome P4502E1 in human liver: relationship between genotype and phenotype in Chinese, Sci China C Life Sci, 44, 356, 10.1007/BF02879602

Tee, 2011, Transcriptional regulation of the human P450 oxidoreductase gene: hormonal regulation and influence of promoter polymorphisms, Mol Endocrinol, 25, 715, 10.1210/me.2010-0236

Tegude, 2007, Molecular mechanism of basal CYP3A4 regulation by hepatocyte nuclear factor 4alpha: evidence for direct regulation in the intestine, Drug Metab Dispos, 35, 946, 10.1124/dmd.106.013565

Teichert, 2009, A genome-wide association study of acenocoumarol maintenance dosage, Hum Mol Genet, 18, 3758, 10.1093/hmg/ddp309

Teichert, 2011, Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes, Pharmacogenet Genomics, 21, 26, 10.1097/FPC.0b013e32834154fb

Telenti, 2008, Pharmacogenetics of anti-HIV drugs, Annu Rev Pharmacol Toxicol, 48, 227, 10.1146/annurev.pharmtox.48.113006.094753

Thangavel, 2011, Intrinsic sexually dimorphic expression of the principal human CYP3A4 correlated with suboptimal activation of GH/glucocorticoid-dependent transcriptional pathways in men, Endocrinology, 152, 4813, 10.1210/en.2011-1274

Thelen, 2009, Cytochrome P450-mediated metabolism in the human gut wall, J Pharm Pharmacol, 61, 541, 10.1211/jpp.61.05.0002

Thompson, 2006, Sequence diversity and haplotype structure at the human CYP3A cluster, Pharmacogenomics J, 6, 105, 10.1038/sj.tpj.6500347

Thorgeirsson, 2010, Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior, Nat Genet, 42, 448, 10.1038/ng.573

Timsit, 2007, CAR and PXR: the xenobiotic-sensing receptors, Steroids, 72, 231, 10.1016/j.steroids.2006.12.006

Tirona, 2003, The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4, Nat Med, 9, 220, 10.1038/nm815

Tomalik-Scharte, 2011, Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide, Drug Metab Dispos, 39, 927, 10.1124/dmd.110.036921

Tomalik-Scharte, 2010, Impaired hepatic drug and steroid metabolism in congenital adrenal hyperplasia due to P450 oxidoreductase deficiency, Eur J Endocrinol, 163, 919, 10.1530/EJE-10-0764

Tornio, 2008, Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone, Drug Metab Dispos, 36, 73, 10.1124/dmd.107.018010

Toscano, 2006, Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events, Pharmacogenet Genomics, 16, 755, 10.1097/01.fpc.0000230112.96086.e0

Trafalis, 2010, CYP2E1 and risk of chemically mediated cancers, Expert Opin Drug Metab Toxicol, 6, 307, 10.1517/17425250903540238

Tsuchiya, 2006, MicroRNA regulates the expression of human cytochrome P450 1B1, Cancer Res, 66, 9090, 10.1158/0008-5472.CAN-06-1403

Turpeinen, 2009, A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes, Drug Metab Dispos, 37, 1017, 10.1124/dmd.108.025700

Turpeinen, 2012, Cytochrome P450 2B6: function, genetics, and clinical relevance, Drug Metabol Drug Interact, 1

Ueda, 2006, A common regulatory region functions bidirectionally in transcriptional activation of the human CYP1A1 and CYP1A2 genes, Mol Pharmacol, 69, 1924, 10.1124/mol.105.021220

Van der Weide, 2003, The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement, Pharmacogenetics, 13, 169, 10.1097/00008571-200303000-00006

Vasiliou, 2008, Role of CYP1B1 in glaucoma, Annu Rev Pharmacol Toxicol, 48, 333, 10.1146/annurev.pharmtox.48.061807.154729

Vieira, 1996, Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period, Eur J Biochem, 238, 476, 10.1111/j.1432-1033.1996.0476z.x

Villeneuve, 2004, Cytochrome P450 and liver diseases, Curr Drug Metab, 5, 273, 10.2174/1389200043335531

Von Richter, 2004, Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens, Clin Pharmacol Ther, 75, 172, 10.1016/j.clpt.2003.10.008

Von Richter, 2004, Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6), Pharmacogenetics, 14, 369, 10.1097/00008571-200406000-00006

Wallemacq, 2009, Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference, Ther Drug Monit, 31, 139, 10.1097/FTD.0b013e318198d092

Walsky, 2004, Validated assays for human cytochrome P450 activities, Drug Metab Dispos, 32, 647, 10.1124/dmd.32.6.647

Wandel, 2000, CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism, Clin Pharmacol Ther, 68, 82, 10.1067/mcp.2000.108506

Wang, 2010, Bupropion metabolism by human placenta, Biochem Pharmacol, 79, 1684, 10.1016/j.bcp.2010.01.026

Wang, 2003, A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression, J Biol Chem, 278, 14146, 10.1074/jbc.M212482200

Wang, 2011, Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs, Pharmacogenomics J, 11, 274, 10.1038/tpj.2010.28

Wang, 2010, Using genetic and clinical factors to predict tacrolimus dose in renal transplant recipients, Pharmacogenomics, 11, 1389, 10.2217/pgs.10.105

Wang, 2009, Ethanol-induced cytochrome P4502E1 causes carcinogenic etheno-DNA lesions in alcoholic liver disease, Hepatology, 50, 453, 10.1002/hep.22978

Wang, 2010, Association between CYP2E1 genetic polymorphisms and lung cancer risk: a meta-analysis, Eur J Cancer, 46, 758, 10.1016/j.ejca.2009.12.010

Wang, 2012, CYP1A2 rs762551 polymorphism contributes to cancer susceptibility: a meta-analysis from 19 case–control studies, BMC Cancer, 12, 528, 10.1186/1471-2407-12-528

Ward, 2003, The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity, J Pharmacol Exp Ther, 306, 287, 10.1124/jpet.103.049601

Wassenaar, 2011, Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk, J Natl Cancer Inst, 103, 1342, 10.1093/jnci/djr237

Watanabe, 2010, Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22), Pharmacogenet Genomics, 20, 459, 10.1097/FPC.0b013e32833bba0e

Waxman, 2009, Sex differences in the expression of hepatic drug metabolizing enzymes, Mol Pharmacol, 76, 215, 10.1124/mol.109.056705

Wei, 2012, Impact of the interaction between 3′-UTR SNPs and microRNA on the expression of human xenobiotic metabolism enzyme and transporter genes, Front Genet, 3, 248, 10.3389/fgene.2012.00248

Wennerholm, 2002, The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity, Clin Pharmacol Ther, 71, 77, 10.1067/mcp.2002.120239

Westlind-Johnsson, 2003, Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism, Drug Metab Dispos, 31, 755, 10.1124/dmd.31.6.755

Widschwendter, 2004, Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen, Cancer Res, 64, 3807, 10.1158/0008-5472.CAN-03-3852

Williams, 2003, Crystal structure of human cytochrome P450 2C9 with bound warfarin, Nature, 424, 464, 10.1038/nature01862

Williams, 2002, Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7, Drug Metab Dispos, 30, 883, 10.1124/dmd.30.8.883

Willmann, 2009, Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study, Clin Pharmacol Ther, 86, 634, 10.1038/clpt.2009.151

Woelderink, 2006, The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies, Pharmacogenomics J, 6, 3, 10.1038/sj.tpj.6500341

Wolbold, 2003, Sex is a major determinant of CYP3A4 expression in human liver, Hepatology, 38, 978, 10.1002/hep.1840380424

Wray, 2009, The epoxygenases CYP2J2 activates the nuclear receptor PPARalpha in vitro and in vivo, PLoS One, 4, e7421, 10.1371/journal.pone.0007421

Wrighton, 1993, Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation, Arch Biochem Biophys, 306, 240, 10.1006/abbi.1993.1506

Wu, 1996, Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart, J Biol Chem, 271, 3460, 10.1074/jbc.271.7.3460

Wyen, 2011, Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens, J Antimicrob Chemother, 66, 2092, 10.1093/jac/dkr272

Xiao, 2009, miRecords: an integrated resource for microRNA–target interactions, Nucleic Acids Res, 37, D105, 10.1093/nar/gkn851

Xie, 2006, Pharmacogenetics of cyclophosphamide in patients with hematological malignancies, Eur J Pharm Sci, 27, 54, 10.1016/j.ejps.2005.08.008

Xie, 2003, Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation, Pharmacogenomics J, 3, 53, 10.1038/sj.tpj.6500157

Xiong, 2011, A systematic genetic polymorphism analysis of the CYP2C9 gene in four different geographical Han populations in mainland China, Genomics, 97, 277, 10.1016/j.ygeno.2010.11.004

Xu, 2009, Influence of genetic polymorphisms on the pharmacokinetics and pharmaco-dynamics of sulfonylurea drugs, Curr Drug Metab, 10, 643, 10.2174/138920009789375388

Xu, 2011, The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases, Adv Drug Deliv Rev, 63, 597, 10.1016/j.addr.2011.03.006

Yamanaka, 2005, CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions, Drug Metab Dispos, 33, 1811

Yamazaki, 1999, Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes, Arch Toxicol, 73, 65, 10.1007/s002040050588

Yamazaki, 2006, Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations, Xenobiotica, 36, 1201, 10.1080/00498250600944318

Yang, 2010, CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection, Expert Opin Drug Metab Toxicol, 6, 29, 10.1517/17425250903386251

Yang, 2010, Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver, Genome Res, 2010, 1020, 10.1101/gr.103341.109

Yao, 2010, Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer, Clin Cancer Res, 16, 6169, 10.1158/1078-0432.CCR-10-0281

Yao, 2010, Lack of significant association between CYP1A1 T3801C polymorphism and breast cancer risk: a meta-analysis involving 25,087 subjects, Breast Cancer Res Treat, 122, 503, 10.1007/s10549-009-0717-2

Yeo, 2011, Discovery of a novel allelic variant of CYP2C8, CYP2C8*11, in Asian populations and its clinical effect on the rosiglitazone disposition in vivo, Drug Metab Dispos, 39, 711, 10.1124/dmd.110.035899

Yimer, 2012, High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a prospective cohort study, Pharmacogenomics J, 12, 499, 10.1038/tpj.2011.34

Yoshinari, 2008, Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements, Biochem Pharmacol, 76, 139, 10.1016/j.bcp.2008.04.005

Yoshinari, 2010, Constitutive androstane receptor transcriptionally activates human CYP1A1 and CYP1A2 genes through a common regulatory element in the 5′-flanking region, Biochem Pharmacol, 79, 261, 10.1016/j.bcp.2009.08.008

Yu, 2003, The relative contribution of monoamine oxidase and cytochrome p450 isozymes to the metabolic deamination of the trace amine tryptamine, J Pharmacol Exp Ther, 304, 539, 10.1124/jpet.102.043786

Yu, 2003, Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6, Pharmacogenetics, 13, 173, 10.1097/00008571-200303000-00007

Yu, 2001, Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19, Clin Pharmacol Ther, 69, 266, 10.1067/mcp.2001.114231

Yuan, 2011, Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent, AIDS, 25, 1271, 10.1097/QAD.0b013e32834779df

Zabalza, 2011, Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel, Heart, 98, 100, 10.1136/hrt.2011.227652

Zanger, 2008, The CYP2D Subfamily, 241

Zanger, 2001, Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6, Pharmacogenetics, 11, 573, 10.1097/00008571-200110000-00004

Zanger, 2008, Polymorphic cytochromes P450 CYP2B6 and CYP2D6: recent advances on single nucleotide polymorphisms affecting splicing, Acta Chim Slov, 55, 38

Zanger, 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance, Pharmacogenomics, 8, 743, 10.2217/14622416.8.7.743

Zanger, 2004, Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry, Naunyn Schmiedebergs Arch Pharmacol, 369, 23, 10.1007/s00210-003-0832-2

Zanger, 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation, Anal Bioanal Chem, 392, 1093, 10.1007/s00216-008-2291-6

Zhai, 2011, Eight common genetic variants associated with serum DHEAS levels suggest a key role in ageing mechanisms, PLoS Genet, 7, e1002025, 10.1371/journal.pgen.1002025

Zhang, 2011, Transcriptional profiling of human liver identifies sex-biased genes associated with polygenic dyslipidemia and coronary artery disease, PLoS One, 6, e23506, 10.1371/journal.pone.0023506

Zhou, 2004, Functional characterization of four allelic variants of human cytochrome P450 1A2, Arch Biochem Biophys, 422, 23, 10.1016/j.abb.2003.11.019

Zhou, 2009, Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2, Drug Metab Rev, 42, 268, 10.3109/03602530903286476

Zuern, 2010, Platelet pharmacogenomics, J Thromb Haemost, 8, 1147, 10.1111/j.1538-7836.2010.03791.x

Zukunft, 2005, A natural CYP2B6 TATA box polymorphism (−82T–>C) leading to enhanced transcription and relocation of the transcriptional start site, Mol Pharmacol, 67, 1772, 10.1124/mol.104.008086